10-Q/A Filing

GUIDED THERAPEUTICS INC CIK: 924515 Q2 2012

Filing Information

Form Type	10-Q/A
Accession Number	`0001121781-12-000291`
Period End Date	20120630
Filing Date	20120824
Fiscal Year	2012
Fiscal Period	Q2
XBRL Instance	gthp-20120630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 68 Income Statement 64 Cash Flow Statement 56

Balance Sheet 68 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$20.00K	USD	Point-in-time
Accounts receivable, net of allowance	`AccountsAndNotesReceivableNet`	$4.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$64.00K	USD	Point-in-time
Inventory, net of reserves	`InventoryFinishedGoodsNetOfReserves`	$64.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.44M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.34M	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $4 and $20 at June 30, 2012 and December 31, 2011	`AccountsReceivableNet`	$139.00K	USD	Point-in-time
Accounts receivable, net of allowance for doubtful accounts of $4 and $20 at June 30, 2012 and December 31, 2011	`AccountsReceivableNet`	$117.00K	USD	Point-in-time
Inventory, net of reserves of $64 at June 30, 2012 and December 31, 2011	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$520.00K	USD	Point-in-time
Inventory, net of reserves of $64 at June 30, 2012 and December 31, 2011	`InventoryNetOfReservesOf64And0AtDecember312011And2010Respectively`	$459.00K	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$39.00K	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	100,000.00	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$54.00K	USD	Point-in-time
Common stock, Authorized	`CommonStockSharesAuthorized`	100,000.00	shares	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	52,211.00	shares	Point-in-time
Total current assets	`AssetsCurrent`	$2.89M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$2.08M	USD	Point-in-time
Common stock, Issued	`CommonStockSharesIssued`	56,166.00	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.03M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	56,166.00	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$1.22M	USD	Point-in-time
Common stock, outstanding	`CommonStockSharesOutstanding`	52,211.00	shares	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$386.00K	USD	Point-in-time
Other assets	`AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment`	$220.00K	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.42M	USD	Point-in-time
Total noncurrent assets	`AssetsNoncurrent`	$1.44M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$4.31M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$3.52M	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	$30.00K	USD	Point-in-time
Short-term notes payable	`ShorttermNotesPayable`	-	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$17.00K	USD	Point-in-time
Current portion of long-term debt	`ShortTermBorrowings`	$25.00K	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	$393.00K	USD	Point-in-time
Notes payable - past due	`NotesPayablePastDue`	$362.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.10M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.07M	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$829.00K	USD	Point-in-time
Accrued liabilities	`AccruedLiabilitiesCurrent`	$757.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$453.00K	USD	Point-in-time
Deferred revenue	`DeferredRevenue`	$772.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$2.73M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$3.08M	USD	Point-in-time
Long-term debt payable, less current portion	`LongtermDebtPayableLessCurrentPortion`	$4.00K	USD	Point-in-time
Long-term debt payable, less current portion	`LongtermDebtPayableLessCurrentPortion`	-	USD	Point-in-time
Total long-term liabilities	`LongTermDebt`	$4.00K	USD	Point-in-time
Total long-term liabilities	`LongTermDebt`	-	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$3.08M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$2.73M	USD	Point-in-time
Common stock, $.001 Par value; 100,000 shares authorized, 56,166 and 52,211 shares issued and outstanding, as of June 30, 2012 and December 31, 2011,respectively	`CommonStockValue`	$52.00K	USD	Point-in-time
Common stock, $.001 Par value; 100,000 shares authorized, 56,166 and 52,211 shares issued and outstanding, as of June 30, 2012 and December 31, 2011,respectively	`CommonStockValue`	$56.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$87.88M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$86.61M	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$104.00K	USD	Point-in-time
Treasury stock, at cost	`TreasuryStockValue`	$104.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-85.09M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-87.50M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$1.47M	USD	Point-in-time
TOTAL GUIDED THERAPEUTICS STOCKHOLDERS' EQUITY	`TotalGuidedTherapeuticsStockholdersEquity`	$334.00K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$104.00K	USD	Point-in-time
Non-controlling interest	`MinorityInterest`	$104.00K	USD	Point-in-time
TOTAL STOCKHOLDERS' EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$438.00K	USD	Point-in-time
TOTAL STOCKHOLDERS' EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$1.58M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$4.31M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$3.52M	USD	Point-in-time

Income Statement 64 line items

Line Item	Tag	Value	Unit	Period
Contract and grant revenue	`Revenues`	$915.00K	USD	1 Quarter
Contract and grant revenue	`Revenues`	$913.00K	USD	1 Quarter
Contract and grant revenue	`Revenues`	$1.63M	USD	2 Qtrs
Contract and grant revenue	`Revenues`	$1.68M	USD	2 Qtrs
Sales - devices and disposables	`SalesDevicesAndDisposables`	$29.00K	USD	1 Quarter
Sales - devices and disposables	`SalesDevicesAndDisposables`	$29.00K	USD	2 Qtrs
Sales - devices and disposables	`SalesDevicesAndDisposables`	-	USD	2 Qtrs
Sales - devices and disposables	`SalesDevicesAndDisposables`	-	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	-	USD	2 Qtrs
Cost of goods sold	`CostOfGoodsSold`	$75.00K	USD	1 Quarter
Cost of goods sold	`CostOfGoodsSold`	$75.00K	USD	2 Qtrs
Cost of goods sold	`CostOfGoodsSold`	-	USD	1 Quarter
Gross Loss	`GrossProfit`	$-46.00K	USD	2 Qtrs
Gross Loss	`GrossProfit`	-	USD	2 Qtrs
Gross Loss	`GrossProfit`	-	USD	1 Quarter
Gross Loss	`GrossProfit`	$-46.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$898.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$619.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.61M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$1.31M	USD	2 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$120.00K	USD	2 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$71.00K	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$139.00K	USD	2 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$69.00K	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.98M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$1.05M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$1.47M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$708.00K	USD	1 Quarter
Total	`OperatingExpenses`	$2.02M	USD	1 Quarter
Total	`OperatingExpenses`	$1.40M	USD	1 Quarter
Total	`OperatingExpenses`	$3.73M	USD	2 Qtrs
Total	`OperatingExpenses`	$2.90M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-485.00K	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-1.23M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-2.14M	USD	2 Qtrs
Operating loss	`OperatingIncomeLoss`	$-1.15M	USD	1 Quarter
OTHER INCOME	`OtherIncome`	-	USD	2 Qtrs
OTHER INCOME	`OtherIncome`	$44.00K	USD	2 Qtrs
OTHER INCOME	`OtherIncome`	$7.00K	USD	1 Quarter
OTHER INCOME	`OtherIncome`	-	USD	1 Quarter
INTEREST EXPENSE	`InterestExpense`	$36.00K	USD	2 Qtrs
INTEREST EXPENSE	`InterestExpense`	$19.00K	USD	1 Quarter
INTEREST EXPENSE	`InterestExpense`	$18.00K	USD	1 Quarter
INTEREST EXPENSE	`InterestExpense`	$41.00K	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$1.17M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$1.22M	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$496.00K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`LossBeforeIncomeTaxes`	$2.18M	USD	2 Qtrs
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	2 Qtrs
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	1 Quarter
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	2 Qtrs
PROVISION FOR INCOME TAXES	`IncomeTaxReconciliationOtherReconcilingItems`	-	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLERS	`NetIncomeLoss`	$-1.22M	USD	2 Qtrs
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLERS	`NetIncomeLoss`	$-2.18M	USD	2 Qtrs
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLERS	`NetIncomeLoss`	$-496.00K	USD	1 Quarter
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLERS	`NetIncomeLoss`	$-1.17M	USD	1 Quarter
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.04	USD	2 Qtrs
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.03	USD	2 Qtrs
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.02	USD	1 Quarter
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	`EarningsPerShareBasicAndDiluted`	$-0.01	USD	1 Quarter
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	53,274.00	shares	2 Qtrs
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	48,464.00	shares	1 Quarter
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	48,159.00	shares	2 Qtrs
WEIGHTED AVERAGE SHARES OUTSTANDING	`WeightedAverageNumberOfSharesOutstandingBasic`	54,077.00	shares	1 Quarter

Cash Flow Statement 56 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-1.22M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-2.18M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-496.00K	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.17M	USD	1 Quarter
Bad debt expense (recovery)	`BadDebtRecovery`	$-8.00K	USD	2 Qtrs
Bad debt expense (recovery)	`BadDebtRecovery`	-	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$8.00K	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$163.00K	USD	2 Qtrs
Stock based compensation	`ShareBasedCompensation`	$350.00K	USD	2 Qtrs
Stock based compensation	`ShareBasedCompensation`	$251.00K	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	-	USD	2 Qtrs
Inventory	`IncreaseDecreaseInInventories`	$61.00K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-64.00K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-14.00K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$15.00K	USD	2 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$8.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-33.00K	USD	2 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-22.00K	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$323.00K	USD	2 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$319.00K	USD	2 Qtrs
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-41.00K	USD	2 Qtrs
Accrued liabilities	`IncreaseDecreaseInAccruedLiabilities`	$74.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$165.00K	USD	2 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$-131.00K	USD	2 Qtrs
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$309.00K	USD	2 Qtrs
Total adjustments	`AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$1.09M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-1.09M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInContinuingOperations`	$-913.00K	USD	2 Qtrs
Additions to capitalized software costs	`CapitalizedComputerSoftwareAdditions`	$-110.00K	USD	2 Qtrs
Additions to capitalized software costs	`CapitalizedComputerSoftwareAdditions`	-	USD	2 Qtrs
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-35.00K	USD	2 Qtrs
Additions to fixed assets	`AdditionsToNoncurrentAssets`	$-351.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-351.00K	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-145.00K	USD	2 Qtrs
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$195.00K	USD	2 Qtrs
Proceeds from options and warrants exercised	`ProceedsFromWarrantExercises`	$690.00K	USD	2 Qtrs
Payments on notes and loan payables	`PaymentsOfLoanCosts`	$62.00K	USD	2 Qtrs
Payments on notes and loan payables	`PaymentsOfLoanCosts`	$11.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$679.00K	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$133.00K	USD	2 Qtrs
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-760.00K	USD	2 Qtrs
NET CHANGE IN CASH AND CASH EQUIVALENTS	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-925.00K	USD	2 Qtrs
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$1.44M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, beginning of year	`CashAndCashEquivalentsAtCarryingValue`	$2.34M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$3.27M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$1.44M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.20M	USD	Point-in-time
CASH AND CASH EQUIVALENTS, end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.34M	USD	Point-in-time
Cash paid for Interest	`InterestPaid`	$11.00K	USD	2 Qtrs
Cash paid for Interest	`InterestPaid`	$1.00K	USD	2 Qtrs
Deemed dividends in the form of convertible warrants into common stock	`DeemedDividendsInFormOfConvertibleWarrantsIntoCommonStock`	$231.00K	USD	2 Qtrs
Deemed dividends in the form of convertible warrants into common stock	`DeemedDividendsInFormOfConvertibleWarrantsIntoCommonStock`	-	USD	2 Qtrs
Conversion of interest to principal	`ConversionOfInterestToPrincipal`	$23.00K	USD	2 Qtrs
Conversion of interest to principal	`ConversionOfInterestToPrincipal`	-	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.